

New Insights in Pyrimidine Antagonist Chemotherapy

The role of Pharmacokinetics and Pharmacogenetics

RIJKSUNIVERSITEIT GRONINGEN

**New Insights in Pyrimidine
Antagonist Chemotherapy**

**The role of Pharmacokinetics
and Pharmacogenetics**

PROEFSCHRIFT

ter verkrijging van het doctoraat in de
Medische Wetenschappen
aan de Rijksuniversiteit Groningen
op gezag van de
Rector Magnificus, dr. F. Zwarts,
in het openbaar te verdedigen op
woensdag 12 januari 2005
om 13.15 uur

door

Jan Gerard Maring

geboren op 19 februari 1967
te Assen

Promotores:

Prof. dr. E.G.E. de Vries
Prof. dr. H.J.M. Groen
Prof. dr. D.R.A. Uges

Beoordelingscommissie:

Prof. dr. J.H. Beijnen
Prof. dr. H.J. Guchelaar
Prof. dr. J. Verweij

**De gezonde mens heeft
Duizend wensen,
De zieke slechts één.**

Ton Luiting, dichter

*Voor mijn ouders
Voor Monique, Sanne en Floor*

The following centres participated in the research described in this thesis: Departments of Pharmacy and Internal Medicine, Diaconessen Hospital Meppel and Bethesda Hospital Hoogeveen; Departments of Medical Oncology, Pulmonary Diseases and Pharmacy, University Hospital Groningen; Departments of Pharmacy and Internal Medicine, Martini Hospital Groningen; Department of Clinical Chemistry, Section Genetic Metabolic Diseases, Academic Medical Centre Amsterdam; Department of Toxicogenetics, Leiden University Medical Centre; Department of Radiation and Stress Cell Biology, University of Groningen.

Financial support for the publication of this thesis was kindly provided by the executive boards of Diaconessen Hospital Meppel and Bethesda Hospital Hoogeveen, the Stichting OZG, Department of Pharmacy, University Hospital Groningen, MerckSharp&Dohme, Novartis Oncology, Eli Lilly, GlaxoSmithKline, Pfizer, Ortho Biotech, Bristol-Myers Squibb, PharmaChemie, Roche and AstraZeneca.

Cover design and layout: Paula Berkemeyer, Amersfoort, www.PBVerbeelding.nl

Photographs on cover and title pages by Jan Gerard Maring

Cover photograph: Architectural polymorphism in shape and colour. Manarola, Cinque Terre Unesco World Heritage, Italy 2001.

Printed by: Ponsen & Looijen b.v., Wageningen, The Netherlands

ISBN: 90-367-2199-7

© 2004 J.G. Maring

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanically, by photocopy, recording or otherwise, without prior written permission of the author.

Contents

Chapter 1	General introduction, objectives and outline.	9
Chapter 2	Genetic factors influencing pyrimidine antagonist chemotherapy.	15
Section A	FOCUS ON FLUOROURACIL	
Chapter 3	A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma.	53
Chapter 4.1	Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics	69
Chapter 4.2	Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.	87
Chapter 5	Dihydropyrimidine dehydrogenase phenotyping in human volunteers and a DPD deficient patient by assessing uracil pharmacokinetics after an oral uracil test dose. A preliminary report.	101
Section B	FOCUS ON GEMCITABINE	
Chapter 6	Selective targeting of homologous DNA recombination repair by gemcitabine	115
Chapter 7	Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC	133
Chapter 8	Gemcitabine and epirubicin plasma concentrations and excretion in saliva in non-small cell lung cancer patients.	151
Chapter 9	Pharmacokinetics and pharmacogenetics of gemcitabine combined with epirubicin or cisplatin in non-small cell lung cancer patients.	163
Summary		177

General discussion and future perspectives	185
Samenvatting	189
Dankwoord	201
Curriculum Vitae	203
List of Publications	205